US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that China's National Medical Products Administration has approved Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) for use in males aged 9 to 26.
This is the first time an HPV vaccine has been authorised for use in males in China.
Gardasil is now indicated to prevent certain HPV-related cancers and diseases, including anal cancer, in males within this age group. The vaccine was previously approved for use in females in China.
Gardasil is a quadrivalent vaccine that protects against human papillomavirus types 6, 11, 16 and 18.
This approval expands the use of Gardasil in China and provides broader protection against HPV-related diseases in the country.
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
European Commission approves GSK's Arexvy for adults aged 18 and over
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic